时隔十年，上证指数重上3800点。 2025年8月22日，A股三大指数集体震荡走强，上证指数收涨逾1%至3825.76点，为近十年来首次站上3800点，沪、深、京三市全天总成交额达2.58万亿 元。自今年二季度以来A股市场持续反弹，相对4月7日的低点，上证指数已大涨近14%。 同样，今年来主动权益基金（包括灵活配置型基金、普通股票型基金、偏股混合型基金在内，以下同）赚钱效应显现。以万得基金指数为例，万得普通股 票型基金指数和万得偏股混合型基金指数年初至今分别大涨24.96%和24.72%，在各大基金指数榜中分别位列第二和第三，仅次于万得QDII混合型基金指 数的27.12%。 来源：Wind（截至2025年8月22日） Wind统计表明，2025年8月22日，年内净值增长率翻倍的主动权益基金（A/C分列，以下同）共计有22只，分别包括长城医药产业精选（A/C）、中银港 股通医药（A/C）、永赢科技智选（A/C）、中信建投北交所精选两年定开（A/C）、永赢医药创新智选（A/C）等。如领涨的长城医药产业精选A和长城 医药产业精选C今年来的净值增长率分别高达130.76%和129.97%。 新经济e线获悉，在年内净 ...

Core Insights - The recent market performance has been strong, with public funds demonstrating significant profit-making ability and excess returns, particularly in themes like Hong Kong securities, innovative pharmaceuticals, and new consumption [1][5] - As of August 18, over 130 funds have achieved returns exceeding 100% in the past year, with notable performances from technology-themed funds focusing on humanoid robots and AI [1][2] Fund Performance - Three North Exchange theme funds have reported returns over 200% in the past year, with specific funds showing returns of 249.27%, 225.42%, and 216.91% respectively [3][4] - A total of 137 funds have achieved returns over 100% in the past year, with many North Exchange theme funds also performing well, including several with returns exceeding 170% [3][4] Active Management and Benchmark Comparison - Actively managed equity funds in the North Exchange have shown significant excess returns compared to their benchmarks, with one fund reporting a return of 190.48% against a benchmark return of 28.64%, resulting in a 161.84 percentage point outperformance [4] Hong Kong Fund Performance - Hong Kong-related funds, particularly in the securities and innovative pharmaceuticals sectors, have also performed well, with one ETF achieving a return of 176% in the past year [5] - Several funds focused on Hong Kong innovative pharmaceuticals have reported impressive returns, with one fund achieving a return of 152.75% year-to-date [5] Technology Fund Performance - Technology-themed funds, particularly those focused on humanoid robots and AI, have also seen significant returns, with one fund reporting a return of 172.28% and another at 174.11% [6] New Consumption and Small Cap Funds - The fund "Guangfa Growth Leading" has achieved a return of 162.55% by capturing new consumption stocks, while some small-cap quantitative funds have also doubled their returns, although risks have been highlighted by several fund companies [7]

Group 1 - The recent market has shown a strong performance, with public funds demonstrating significant profit-making ability and excess returns, particularly in themes like Hong Kong securities, innovative pharmaceuticals, and new consumption [1][2] - As of August 18, over 130 funds have achieved returns exceeding 100% in the past year, with three North Exchange theme funds reporting returns over 200% [1][2] - Notably, the top-performing North Exchange funds include those managed by Citic Securities and Huaxia, with returns of 249.27% and 225.42% respectively [1][2] Group 2 - Active management equity funds in the North Exchange have shown significant excess returns compared to their benchmarks, with one fund reporting a return of 190.48% against a benchmark return of 28.64% [2] - Hong Kong-related funds, especially in the securities and innovative pharmaceuticals sectors, have also performed well, with the E Fund Hong Kong Securities Investment Theme ETF achieving a return of 176% [2][3] - The performance of the E Fund ETF has been bolstered by a surge in trading volume, reaching nearly 120 billion yuan in a week, marking a record high since its launch [2] Group 3 - Several technology-themed funds have also reported impressive returns, such as the Yongying Advanced Manufacturing Fund, which focuses on humanoid robots and has a return of 172.28% [3] - The China Europe Digital Economy Fund, which targets artificial intelligence sectors, has achieved a return of 174.11% [3] - The growth of new consumption stocks has significantly contributed to the performance of funds like the GF Growth Navigator, which has a return of 162.55% [4]

Core Insights - The public fund performance in the first half of 2025 reveals an unexpected phenomenon, with the pharmaceutical and North Exchange sectors dominating the top returns, showcasing significant gains despite market anxieties [2][9]. Group 1: Fund Performance - The top-performing fund, Huatai-PineBridge Hong Kong Advantage Selection (QDII fund), achieved a nearly 98% year-to-date increase, driven by a contrarian strategy during a challenging market environment [4]. - Changcheng Pharmaceutical Selection ranked second with an 81.45% return, led by a new fund manager who focused on innovative and commercially viable companies [5]. - CITIC Securities North Exchange Selection achieved an 80.95% return, showcasing a remarkable turnaround with a nearly doubled net value in under a year [6]. - Bank of China Hong Kong Stock Connect Pharmaceutical fund recorded a 77.14% return, employing a high-growth, high-barrier investment strategy [7]. - Yongying Pharmaceutical Innovation Selection reached a 76.76% return, utilizing a dual-manager strategy to balance performance and risk [8]. Group 2: Investment Strategies - The successful funds employed diverse strategies, including contrarian approaches, multi-asset allocation, and a focus on undervalued growth opportunities [4][6][9]. - The emphasis on pharmaceutical innovation and the valuation recovery of the North Exchange "specialized and innovative" companies were pivotal in driving the capital market's performance [9][10]. - The collective success of these funds highlights the importance of deep research, differentiated positioning, and the courage to go against market trends [9][10].

Core Viewpoint - The active equity fund managed by CITIC Construction Investment's North Exchange has achieved the highest performance in the first half of the year, with a return of 82.45% as of June 30 [1] Fund Performance Summary - The top-performing fund is the CITIC Construction Investment North Exchange Selected Two-Year Open Fund, led by Leng Wenpeng, with a return of 82.45% [1] - Other notable funds include: - Huaxia North Exchange Innovation Small and Medium Enterprises Selected Two-Year Open Fund with a return of 72.16% [1] - Wanji North Exchange Intelligent Selection Two-Year Open Fund with a return of 60.36% [1] - The second-ranked fund, Changcheng Pharmaceutical Industry Selected Fund, achieved a return of 75.18% [1] - More than half of the top ten funds have significant investments in the pharmaceutical sector, including: - Bank of China Hong Kong Stock Connect Pharmaceutical Fund with a return of 70.08% [1] - Yongying Pharmaceutical Innovation Intelligent Selection Fund with a return of 69.39% [1] - Huashan Pharmaceutical Biotechnology Fund with a return of 66.44% [1] - Ping An Core Advantage Fund with a return of 63.76% [1] - Nuon Selected Value Fund with a return of 61.88% [1] - The growth-oriented fund managed by Wu Yuanyi, Guangfa Growth Navigation One-Year Holding, ranked sixth with a return of 68.29% [1]

Group 1 - As of June 29, over 80% of public funds have achieved positive returns in 2025, with the top fund, Huatai-PineBridge Hong Kong Advantage Selection, showing a remarkable increase of 89.15% [1] - The competition among public funds is intense, with the top two funds having an 8 percentage point difference in returns, while the third to fifth funds have a narrower margin of only 2 percentage points [1] - The leading funds over the past three to five years have shown significant growth, with Jin Yuan Shun An Yuan Qi achieving nearly 300% over five years, surpassing the second-place fund by over 90 percentage points [1] Group 2 - Approximately 80% of public funds with over 50% returns this year were heavily invested in the pharmaceutical sector by the end of Q1 2025, particularly in innovative drug companies [2] - The top fund, Huatai-PineBridge Hong Kong Advantage Selection, had all of its top ten holdings in innovative drug stocks, with notable performers like Rongchang Bio and Nuo Cheng Jian Hua seeing increases of up to 285.76% [2] - The fund manager emphasized that innovative drugs will be a crucial theme in the pharmaceutical industry for the coming years, focusing on companies with core competitiveness and long-term growth potential [2] Group 3 - The third-ranked fund, Great Wall Pharmaceutical Industry Selection, also focused on innovative drugs, with all top ten holdings showing over 30% gains this year [3] - The fund manager noted that the current landscape for innovative drug stocks is favorable due to advancements in overseas collaborations and improved financial reports [3] - The fund's strategy includes investing in companies with disruptive innovations and those that have begun commercializing their products, leading to rapid financial improvements [3] Group 4 - Two funds heavily invested in the Beijing Stock Exchange have performed well, with CITIC Securities Beijing Stock Exchange Selection achieving a return of 81.59% and Huaxia Beijing Stock Exchange Innovative Small and Medium Enterprises Selection at 71.92% [4] - The top ten holdings of CITIC Securities fund have all shown positive returns, with seven stocks increasing over 30%, and one stock, Wantong Hydraulic, exceeding 90% [4] - The fund manager expressed optimism about the long-term investment potential of companies listed on the Beijing Stock Exchange, despite the need for cautious positioning in uncertain market conditions [4] Group 5 - Many of the top-performing public funds this year are small-scale products, with half of the top ten funds having a size of less than 100 million yuan [5] - In larger funds, performance is often driven by index products, with several ETFs showing strong returns [5] - The relationship between fund size and performance suggests that larger funds may dilute their aggressive investment strategies due to the need to diversify holdings [6] Group 6 - Among actively managed equity funds with over 10 billion yuan, only a few have achieved returns exceeding 10% this year, indicating challenges faced by larger funds [6] - Industry experts suggest that larger funds may struggle to adapt quickly to market changes, impacting their performance [6] - Looking ahead, many fund companies believe that investment opportunities in A-shares will outweigh risks, with a focus on sectors like technology, pharmaceuticals, and consumer goods [6]

Core Viewpoint - A significant number of active equity funds are experiencing a performance turnaround, with over 180 funds reaching new historical net asset value highs as of June 25, driven by market uptrends and favorable external factors [1][2]. Group 1: Performance of Active Equity Funds - Over 180 active equity funds have achieved historical net asset value highs, with more than half of these funds established for over a year, and some for nearly 14 years [1][2]. - The fund with the highest increase is Jin Yuan Shun An Yuan Qi, which has risen over 450% since its inception in November 2017, primarily investing in small-cap stocks [2][3]. - Other notable funds include Guangfa Multi-Factor and Dacheng Jingheng, with increases of over 340% and nearly 300% respectively, focusing on quantitative investment strategies [2][3]. Group 2: Market Trends and Investment Strategies - Approximately 80% of active equity funds have seen positive performance this year, with around 1,100 funds increasing by over 10%, particularly those focused on Hong Kong stocks, pharmaceuticals, and technology [3][4]. - The highest-performing fund this year is Huatai-PB Hong Kong Advantage Selection, which has increased by over 90%, primarily investing in the Hong Kong pharmaceutical sector [4]. - Three main investment directions have gained consensus among institutions: innovative pharmaceuticals, technology, and dividend stocks, with a preference for a "barbell" strategy that balances aggressive and defensive investments [4][5]. Group 3: Future Outlook and Recommendations - Fund managers suggest focusing on high-potential international pharmaceutical companies and stable dividend assets, especially in a declining interest rate environment [5][6]. - The AI sector is highlighted as a key area for investment, with significant growth in AI applications and user engagement noted [6][7]. - Overall, there is optimism for the A-share market, with recommendations to prioritize stable dividend returns and sectors with strong industrial and policy catalysts [7].

每经记者｜曾子建 每经编辑｜赵云 已结束的5月行情中，A股市场震荡上行。沪指月涨幅2.09%，深证成指上涨1.42%，科创50指数下跌3.50%。 指数表现差异明显，也意味着相关公募基金的业绩出现较大分化。截至5月末，公募基金业绩榜上，多只长期名列前茅的产品，业绩明显回落；又一批产品 后来居上，占据涨幅榜前列。 混合型基金涨幅榜： 北交所产品领涨，4月底的"冠军基"跌至10名开外 先看混合型基金涨幅榜的巨大变化。 和4月末的榜单相比，此前重仓布局机器人板块的鹏华碳中和、前海开源嘉鑫和永赢先进制造智选的业绩明显回撤，排名分别从此前的第1、第2、第4，滑落 至第13、第19和第20。 目前排名第1和第2的是中信建投北交所精选两年定开，以及华夏北交所创新中小企业精选两年定开，年内业绩分别为69.30%和67.38%。 | 证券代码 | 证券简称 | | 近1月回报 [单位] % 近3月回报 [单位] % | 近1年回报 [单位] % 今年以来 [单位] % | | 其余经 | | --- | --- | --- | --- | --- | --- | --- | | 016303.OF | 中信建投北交所精选两年定 ...

Group 1: Core Insights - The public fund market in Q1 2025 performed well, driven by AI and robotics, with robotics-themed funds, North Exchange funds, and Hong Kong stock funds leading the performance rankings [1][5] - The top-performing fund, Penghua Carbon Neutrality Theme A, achieved a return of 60.26%, making it the champion of Q1 performance [1][2] - Active equity funds showed a significant recovery, outperforming passive products due to their flexible market strategies and early positioning in high-performing stocks [1][5] Group 2: Robotics-Themed Funds - Robotics-themed funds stood out in Q1 2025, with Penghua Carbon Neutrality Theme A heavily invested in stocks like Beite Technology and Hechuan Technology, achieving a 60.26% return [2] - Notable stocks contributing to the fund's success included Shuanglin Co., which saw a year-to-date increase of 118.16% [2] - Fund managers expressed optimism about the robotics sector, highlighting investment opportunities in areas such as electronic skin and laser radar [2] Group 3: North Exchange Funds - North Exchange funds also performed well, with returns of 38.98%, 37.45%, and 34.26% for specific funds, driven by investments in stocks like Kelaite, which increased by 136.01% [3] - The North Exchange market is viewed as having reasonable valuations, with potential for growth due to the continuous inclusion of innovative companies [3] Group 4: Hong Kong Stock Funds - Hong Kong stock funds experienced a resurgence, with returns of 38.9%, 32.25%, and 31.4%, primarily driven by strong performances in the internet technology and pharmaceutical sectors [4] - Key stocks included Hansoh Pharmaceutical and Kelong Biotechnology, which saw significant price increases of 78.08% and 64.58%, respectively [4] - Fund managers anticipate continued growth in the pharmaceutical sector due to improved R&D efficiency and increasing transaction shares from overseas pharmaceutical companies [4] Group 5: Active Equity Funds - Active equity funds demonstrated strong performance, with an average net value growth rate of 3.47%, significantly outperforming mainstream indices [5] - Ordinary stock funds and mixed equity funds reported average net value growth rates of 4.57% and 4.53%, respectively, showcasing the strong capabilities of public funds in equity investment [5] - The overall market in Q1 2025 exhibited structural characteristics, with robotics-themed funds leading the way and active equity funds marking a recognition of fund managers' stock-picking abilities [5]

一批北交所主题基金净值新高。 北交所持续走强，市场交投活跃，同泰基金对记者分析，这反映了市场对北交所高质量扩容和流动性改善的认 可，更体现了在技术进步、行业产业景气度提升大背景下，市场对于北交所上市企业业绩增长的长期信心。 开年以来，除了机器人、港股科技等主题基金业绩一路飙涨之外，较为小众化的北交所主题基金也表现强势， 今年全部实现18%以上正收益，其中同泰远见、广发北证50成份等25只北交所主题基金净值涨幅超30%。 机构表示，北交所市场反弹离不开支持政策不断出台、机构投资多元化、市场流动性提升、基本面改善等多重 利好。 在北交所已经大幅反弹的当下，机构认为，短期需审慎优选估值合理的标的进行配置，不过中长期来看，其作 为"专精特新"企业孵化器的定位明确，叠加流动性改善与高质量扩容，结构性机会将不断涌现。 北交所主题基金表现强势 近期，北交所主题基金成为市场上除机器人、港股科技之外表现最强的主题基金之一。 今年以来，北交所主题基金全部实现正收益，其中同泰远见、广发北证50成份、博时北证50成份等25只北交所 主题基金净值涨幅均超30%，引发市场广泛关注。 目前市场上共计超30只北交所主题基金，其中22只基金为 ...